Fundraising FoxCvergenx, Inc
Tampa, US · Delaware corporation · 1 known investors
Find your way into Cvergenx, Inc
Sign up to see every warm intro you have to Cvergenx, Inc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cvergenx, Inc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CvergenX develops the precisionRT Dose (pRTD) platform, which uses gene-expression biomarkers (RSI) and the Genomic Adjusted Radiation Dose (GARD) metric to predict tumor radiosensitivity and personalize radiotherapy dosing. It provides predictive analytics for biologically guided radiation oncology, serving clinical and research use in cancer treatment.
Founders & leadership
JT
Javier Torres-Roca, M.D.Secretary & Treasurer
SE
Steven Eschrich, Ph.D.Chief Technology Officer
RF
Raymond F. VennareChairman and CEO2015–2022Raymond F. Vennare is President and Chief Executive Officer of CvergenX, a company developing the precisionRT Dose platform for personalized radiotherapy dosing. He has over thirty years of experience in biotechnology executive roles, company building, technology commercialization, and corporate governance.
Board
MB
MaryDel BradyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$390K disclosed across 1 of 3 rounds · 2011–2017
▶$2.5MofferedJul 2017 · OtherRule 506(b)
▶$2.5MofferedJul 2017 · Other
Rule 506(b)Officers, directors & promoters on the filing
- Raymond F. VennareExecutive Officer, Director
- Javier Torres-Roca, M.D.Executive Officer, Director
- Steven Eschrich, Ph.D.Executive Officer, Director
- Offering amount
- $2.5M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KofferedMay 2016 · OtherRule 506(c)
▶$500KofferedMay 2016 · Other
Rule 506(c)Officers, directors & promoters on the filing
- Steven Eschrich, Ph.D.Executive Officer, Director
- Javier Torres-Roca, M.D.Executive Officer, Director
- Raymond F. VennareExecutive Officer, Director
- Offering amount
- $500K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$390KraisedMay 2016 · 10 investors · OtherRule 506(b)
▶$390KraisedMay 2016 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Raymond F. VennareExecutive Officer, Director
- Javier Torres-Roca, M.D.Executive Officer, Director
- Steven Eschrich, Ph.D.Executive Officer, Director
- MaryDel BradyDirector
- Offering amount
- $390K
- Amount sold
- $390K
- First sale
- Apr 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Cvergenx, Inc do?
- CvergenX develops the precisionRT Dose (pRTD) platform, which uses gene-expression biomarkers (RSI) and the Genomic Adjusted Radiation Dose (GARD) metric to predict tumor radiosensitivity and personalize radiotherapy dosing. It provides predictive analytics for biologically guided radiation oncology, serving clinical and research use in cancer treatment.
- Who founded Cvergenx, Inc?
- Cvergenx, Inc was founded by Javier Torres-Roca, M.D., Steven Eschrich, Ph.D..
- Who are Cvergenx, Inc's investors?
- Cvergenx, Inc's investors include Tamiami Angel.
- How much funding has Cvergenx, Inc raised?
- Cvergenx, Inc has disclosed $390K raised across 1 of its 3 known rounds.
- Where is Cvergenx, Inc headquartered?
- Cvergenx, Inc is headquartered in Tampa, US.